Q3 FY22 Earnings Presentation

Cardiovascular (continued) Growth despite COVID-19 headwinds; share gains continue in CRM Coronary and Peripheral Vascular Coronary & Renal Denervation ▼ MSD Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions ESG Appendix • PCI procedures remain below pre-COVID levels in U.S. and Western Europe; stable share Prevail TM DCB launch underway in EU 3-year data from SPYRAL HTN-ON MED pilot study to be presented at ACC'22 Peripheral Vascular Health LDD Continued ramp of the AbreTM Deep Venous stent and MSD growth in Superficial Venous Structural Heart & Aortic Structural Heart Mid-teens Evolut™ Pro TAVR System approved in China for severe AS symptomatic patients at high/extreme risk with commercial launch expected in Q4; OPTIMIZE PRO trial enrollment completed Evolut™ FX TAVR System Abre™ Deep Venous Stent • • First transfemoral (TF) case in APOLLO mitral pivotal trial recently completed Aortic Mid-20s TAA sequential growth as Valiant Captivia TM supply improves; continued pressure from Navion™ recall Cardiac Surgery LDD Share gains driven by continued penetration into ECLS and CABG markets 13 | Q3 FY22 earnings presentation | February 22, 2022 Cardiovascular 27% Structural Heart & Aortic O 22% Coronary & Peripheral Vascular Medtronic $51% Cardiac Rhythm & Heart Failure

View entire presentation